Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors

Oncotarget. 2016 Dec 6;7(49):81341-81356. doi: 10.18632/oncotarget.13228.

Abstract

Squamous cell carcinoma (SCC) is the second commonest type of skin cancer. Moreover, about 90% of head and neck cancers are SCCs. SCCs develop at a significantly higher rate under chronic immunosuppressive conditions, implicating a role of immune surveillance in controlling SCCs. It remains largely unknown how SCCs evade immune recognition. Here, we established a mouse model by injecting tumor cells derived from primary SCCs harboring KrasG12D mutation and Smad4 deletion into wild-type (wt) or CD8-/- recipients. We found comparable tumor growth between wt and CD8-/- recipients, indicating a complete escape of CD8+ T cell-mediated anti-tumor responses by these SCCs. Mechanistically, CD8+ T cells apparently were not defective in infiltrating tumors given their relatively increased percentage among tumor infiltrating lymphocytes (TILs). CD8+ TILs exhibited phenotypes of chronic activation and exhaustion, including overexpression of activation markers, co-expression of programmed cell death 1 (PD-1) and lymphocyte activation gene-3 (LAG-3), as well as TCRβ downregulation. Among CD4+ TILs, T regulatory cells (Tregs) were preferentially expanded. Contradictory to prior findings in melanoma, Treg expansion was independent of CD8+ T cells in our SCC model. Unexpectedly, CD8+ T cells were required for promoting NK cell infiltration within SCCs. Furthermore, we uncovered AKT-dependent lymphocyte-induced PD-L1 upregulation on SCCs, which was contributed greatly by combinatorial effects of CD8+ T and NK cells. Lastly, dual blockade of PD-1 and LAG-3 inhibited the tumor growth of SCCs. Thus, our findings identify novel immune evasion mechanisms of SCCs and suggest that immunosuppressive mechanisms operate in a cancer-type specific and context-dependent manner.

Keywords: LAG-3; PD-1; Smad4 loss; immune evasion; squamous cell carcinoma.

MeSH terms

  • Animals
  • Antigens, CD / immunology
  • Antigens, CD / metabolism*
  • Antineoplastic Agents, Immunological / pharmacology
  • CD8 Antigens / deficiency
  • CD8 Antigens / genetics
  • CD8 Antigens / metabolism*
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / metabolism*
  • CD8-Positive T-Lymphocytes / pathology
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / metabolism*
  • Carcinoma, Squamous Cell / pathology
  • Cell Line, Tumor
  • Coculture Techniques
  • Cytoprotection
  • Gene Deletion
  • Genetic Predisposition to Disease
  • Humans
  • Lymphocyte Activation Gene 3 Protein
  • Lymphocyte Activation* / drug effects
  • Lymphocytes, Tumor-Infiltrating / drug effects
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / metabolism*
  • Lymphocytes, Tumor-Infiltrating / pathology
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mutation
  • Phenotype
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / immunology
  • Programmed Cell Death 1 Receptor / metabolism*
  • Proto-Oncogene Proteins p21(ras)
  • Signal Transduction
  • Smad4 Protein
  • Time Factors
  • Tumor Burden
  • Tumor Escape* / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, CD
  • Antineoplastic Agents, Immunological
  • CD8 Antigens
  • KRAS protein, human
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • SMAD4 protein, human
  • Smad4 Protein
  • Proto-Oncogene Proteins p21(ras)
  • Lymphocyte Activation Gene 3 Protein